CSAClinical-Stage Asset Intelligence
Catalyst calendar Get the data
Home / Immutep LTD (IMMP) / eftilagimod alfa
Forward catalyst · IMMP

eftilagimod alfa

Sponsor Immutep LTD · listed as IMMP

READOUT Phase 3 Confidence: medium Source: clinicaltrials

eftilagimod alfa is a drug asset sponsored by Immutep LTD, listed as IMMP. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Jun 2027 (month precision, medium confidence), tied to trial NCT06726265. That trial is in Phase 3 and currently active not recruiting, studying Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC).

Next catalyst

Event typeREADOUT
Expected date2027-06-30
As disclosedJun 2027
Date precisionmonth
Confidencemedium
Verify at source →

Trial & sponsor

Trial (NCT)NCT06726265
PhasePHASE3
StatusACTIVE_NOT_RECRUITING
Lead sponsorImmutep S.A.S.
Listed asIMMP
Condition(s)Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
!

Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.

This page is one record from the free CSA sample. The full snapshot covers active, industry-sponsored Phase 3 trials in cardiometabolic, oncology and immunology. Every forward catalyst carries its date, confidence grade and source link, and is linked to its sponsor's ticker when the sponsor is a listed company.

Get the full dataset — $499 →   More IMMP catalysts

Related catalysts and sponsor